| (Values in U.S. Thousands) | Dec, 2019 | Sep, 2019 | Jun, 2019 | Mar, 2019 | Dec, 2018 |
| Sales | 11,330 | 6,670 | 7,390 | 7,250 | 8,950 |
| Sales Growth | +69.87% | -9.74% | +1.93% | -18.99% | +27.67% |
| Net Income | -4,940 | -10,780 | -10,470 | -9,000 | -6,440 |
| Net Income Growth | +54.17% | -2.96% | -16.33% | -39.75% | +9.42% |
Correvio Pharma Corp (CORV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Correvio Pharma Corp. operates as a pharmaceutical company. It develops and discovers cardiovascular drugs for the treatment of atrial arrhythmia, congestive heart failure and bacterial skin infections. The company's product portfolio includes BRINAVESS(R), AGGRASTAT(R), ESMOCARD(R), ESMOCARDLYO(R), EXEMBOL(R) and XYDALBA(TM). Correvio Pharma Corp., formerly known as Correvio Pharma Corp., is based in Vancouver, Canada.
Fiscal Year End Date: 12/31